• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
M P D U
M P D U

... Medicare Part B Payments for Prescription Drugs CMS contracts with private companies (i.e., contractors) to process and pay Medicare Part B claims, including those for prescription drugs. 3 To obtain payment for covered outpatient prescription drugs, health care providers submit claims to their Medi ...
Poonam et al - Galaxy of Pharmaceutical Innovations
Poonam et al - Galaxy of Pharmaceutical Innovations

... the bad taste. For example, sweeteners could not achieve taste masking of oral formulation of ibuprofen due to its dominating taste. Coating is more efficient technology for aggressively bitter drugs even though coating imperfections, if present, reduce the efficiency of the technique9. Similarly, m ...
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC

... circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceu ...
Addiction neurobiology: Ethical and social implications
Addiction neurobiology: Ethical and social implications

... provided a deeper appreciation of how social factors, such as socio-economic status, upbringing, and exposure to abuse or violence, particularly while young, can interact with individuals’ genetic make-up, leaving them at a higher risk of using drugs, and more vulnerable to developing addiction if t ...
Biowaiver extension potential to BCS Class III high solubility
Biowaiver extension potential to BCS Class III high solubility

... Thus, it is evident that if the formulation of metformin IR product is rapid dissolving, dissolution will not affect availability of metformin. Using the rationale of the BCS, it can be argued that biowaivers can be granted for metformin IR products on the basis of in vitro dissolution profiles. The ...
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC

... circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceu ...
PDF version of March 2015 PBAC Meeting Agenda
PDF version of March 2015 PBAC Meeting Agenda

... circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceu ...
TASTE MASKING TECHNOLOGIES: A REVIEW  Review Article SHALINI SHARMA AND SHAILA LEWIS* 
TASTE MASKING TECHNOLOGIES: A REVIEW  Review Article SHALINI SHARMA AND SHAILA LEWIS* 

... It  can  be  seen  that  tongue  is  10,000  times  more  senstive  to  the  bitternes of  quinine than  to sweetness  of sugar. Saccharine, on this  scale would rate about 0.001%.   Pharmaceutical  companies  can  save  themselves  much  grief  by  addressing  the  taste  factor  early  in  the  pr ...
FOOD AND DRUG ADMINISTRATION, et al
FOOD AND DRUG ADMINISTRATION, et al

... The "intended use" concept originated in the Pure Food and Drugs Act of 1906, which focused on manufacturer statements on the product label. Over the decades, that meaning became tightly woven into the fabric of the FDCA. Its lengthy history and its role in the structure and established operation of ...
Potential Drug Interactions - edoc
Potential Drug Interactions - edoc

... potassium-sparing diuretics, and/or NSAIDs or COX-2 selective inhibitors. Risk factors associated with a high velocity to develop hyperkalaemia were in descending order: use of potassium supplements, severe renal impairment, use of potassiumsparing diuretics, use of ACEIs or ARBs, and diabetes melli ...
IMC Analysis Pfizer`s Zoloft 1 IMC ANALYSIS
IMC Analysis Pfizer`s Zoloft 1 IMC ANALYSIS

... felt starting in 2005 with the effects of competition and increased scrutiny from regulators (Wilson, 2009). As a result Pfizer is in process of cutting costs and finding new drugs. CEO Jeff Kindler promised and met the goal to cut $2 billion in costs by the end of 2008 (Wilson, 2009). Other goals i ...


... Background.—Updated guidelines for the preventive treatment of episodic migraine have been issued by the American Headache Society (AHS) and the American Academy of Neurology (AAN). We summarize key 2012 guideline recommendations and changes from previous guidelines. We review the characteristics, m ...
Forensic Toxicology PPT
Forensic Toxicology PPT

... • The drug produces a sedative effect, amnesia, muscle relaxation, and a slowing of psychomotor responses. • Sedation occurs 20-30 minutes after administration and lasts for hours. • The drug is not commonly used by physicians in the US. • The drug has been added to drinks at parties, where it is re ...
Comparison of the effects of cimetidine and hyoscine-n
Comparison of the effects of cimetidine and hyoscine-n

... The concentration of Paracetamol in the plasma samples prepared above was then determined using an adaptation of the UV spectrophotometric method of Glynn and Kendal [47]. A 2ml of 15% trichloroacetic acid was added to the 1ml of plasma prepared above and vortex mixed. The sample was then centrifuge ...
1 Anish et al Journal of Drug Delivery & Therapeutics; 2012, 2(1)
1 Anish et al Journal of Drug Delivery & Therapeutics; 2012, 2(1)

... of both the body and the mind. However dedicated research from scientists all over the world has made it possible to treat, prevent and eradicate many of these diseases that plague man. The field of pharmaceutical science has been developing steadily over the years, and has today become invaluable i ...
Antiparasitic Chemotherapy for Human and Veterinary Use 3rd
Antiparasitic Chemotherapy for Human and Veterinary Use 3rd

... 9:20 Descoteaux A., INRS- Institut Armand-Frappier, Laval, Canada (COST invited ...
Full-Text  - Academic Journals
Full-Text - Academic Journals

... extract that has a greater affinity with hemin maintains more hemin in solution and is thus more effective. This ...
PDF - Innovare Academic Sciences
PDF - Innovare Academic Sciences

... Successful oral delivery of drugs has always remained a challenge to the drug delivery field, since approximately 40% of the new drug candidates have poor water solubility, and thus oral delivery is frequently associated with implications of low bioavailability. Today, a large percent of the new che ...
Charles University in Prague Faculty of Pharmacy in Hradec Králové
Charles University in Prague Faculty of Pharmacy in Hradec Králové

... Tuberculosis (TB) is an infectious bacterial disease caused by Mycobacterium tuberculosis (M. tbc.), which most commonly affects the lungs but can also affect the central nervous system, the lymphatic system, the circulatory system, the genitourinary system, the gastrointestinal system, bones, joint ...
March 2017 PBAC Meeting Agenda (Word 67KB)
March 2017 PBAC Meeting Agenda (Word 67KB)

... circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceu ...
Target Regimen Profiles for TB Treatment
Target Regimen Profiles for TB Treatment

... There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of target product profiles for TB drug regimens (hereafter referred as target regimen profiles) is meant to assist drug regimen developers in identifying important regi ...
Report of the International Narcotics Control Board for 2015
Report of the International Narcotics Control Board for 2015

... driving towards improving public health and welfare, based on the underlying principles of proportionality, collective responsibility and compliance with international human rights standards. Implementing this system means putting the health and welfare of mankind at the core of drug policies, apply ...
National report 2014: Poland - European Monitoring Centre for
National report 2014: Poland - European Monitoring Centre for

... Please use the following citation (Dla przypisów bibliograficznych): Malczewski, A., Misiurek, A., Bukowska, B., Chojecki, D., Jabłoński, P., Kidawa, M., Leszczyńska, M., Poleganow, A., Radomska, A., Struzik, M., Stawecka, E., Struzik, M., Strzelecka, A., Twierdziańska, A., Walichnowska, M. (2015), ...
THE ROLE OF CYP3A4/5 IN ALPRAZOLAM METABOLISM
THE ROLE OF CYP3A4/5 IN ALPRAZOLAM METABOLISM

... Therapeutic drug monitoring Thiopurine methyltransferase UDP-glucuronosyltranseferase enzymes Maximum rate of formation ...
Express Scripts 2015 Drug Trend Report
Express Scripts 2015 Drug Trend Report

... system to fight cancer. In addition to newer products, medications like Xtandi® (enzalutamide) are used to help patients delay the need to start chemotherapy. These therapies have positive impacts on patient care but come with a hefty price tag – averaging more than $8,000 per prescription. Increasi ...
< 1 2 3 4 5 6 7 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report